Abstract
Introduction: Chromosomal abnormalities (CAs) have been identified as important factors in determining the biological features and prognostic value of multiple myeloma (MM). MYC gene-related abnormalities (MYC GAs) are one of the CAs, but their unfavorable impact has not been fully investigated in daily clinical practice. Methods: This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute. Results: MYC GAs were associated with poor overall survival (hazard ratio [HR], 3.08; 95% confidence interval [CI]: 1.23–7.73; p = 0.017), progression-free survival (PFS) (HR, 2.96; 95% CI: 1.58–5.53; p < 0.001), and time to next treatment (TNT) (HR, 2.11; 95% CI: 1.13–3.93; p = 0.018) in the median follow-up of 34.7 months. Furthermore, MYC GAs with an additional chromosome 8 (MYC-Ch8(+)) were associated with shorter PFS (HR, 3.15; 95% CI: 1.38–7.2; p = 0.0064), whereas MYC GAs without an additional chromosome 8 (MYC-Ch8(−)) were associated with shorter PFS (HR, 3.62; 95% CI: 1.51–8.68; p = 0.004) and shorter TNT (HR, 3.72; 95% CI: 1.41–9.81; p = 0.0078). Conclusion: These findings could help identify high-risk patients with MM. Further prospective studies are needed to confirm the significance of MYC GAs for the MM prognostic effect.
References
1.
Ross
FM
, Avet-Loiseau
H
, Ameye
G
, Gutiérrez
NC
, Liebisch
P
, O’Connor
S
, Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
. Haematologica
. 2012
;97
(8
):1272
–7
.2.
Palumbo
A
, Avet-Loiseau
H
, Oliva
S
, Lokhorst
HM
, Goldschmidt
H
, Rosinol
L
, Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group
. J Clin Oncol
. 2015
;33
(26
):2863
–9
.3.
Walker
BA
, Wardell
CP
, Brioli
A
, Boyle
E
, Kaiser
MF
, Begum
DB
, Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
. Blood Cancer J
. 2014
;4
:e191
.4.
Weinhold
N
, Kirn
D
, Seckinger
A
, Hielscher
T
, Granzow
M
, Bertsch
U
, Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma
. Haematologica
. 2016
;101
(3
):e116
–9
.5.
Sekiguchi
N
, Ootsubo
K
, Wagatsuma
M
, Midorikawa
K
, Nagata
A
, Noto
S
, Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy
. Int J Hematol
. 2014
;99
(3
):288
–95
.6.
Türkmen
S
, Binder
A
, Gerlach
A
, Niehage
S
, Theodora Melissari
M
, Inandiklioglu
N
, High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS
. Genes Chromosomes Cancer
. 2014
;53
(8
):650
–6
.7.
Affer
M
, Chesi
M
, Chen
WG
, Keats
JJ
, Demchenko
YN
, Roschke
AV
, Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
. Leukemia
. 2014
;28
(8
):1725
–35
.8.
Mikulasova
A
, Ashby
C
, Tytarenko
RG
, Qu
P
, Rosenthal
A
, Dent
JA
, Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
. Haematologica
. 2020
;105
(4
):1055
–66
.9.
García
R
, Chen
W
, Koduru
P
. Clinical impact of MYC abnormalities in plasma cell myeloma
. Cancer Genet
. 2018
;228–9
:115
–26
.10.
Mlynarcikova
M
, Balcarkova
J
, Mickova
P
, Scudla
V
, Pika
T
, Bacovsky
J
, Molecular cytogenetic analysis of chromosome 8 aberrations in patients with multiple myeloma examined in 2 different stages, at diagnosis and at progression/relapse
. Clin Lymphoma Myeloma Leuk
. 2016
;16
(6
):358
–65
.11.
Glitza
IC
, Lu
G
, Shah
R
, Bashir
Q
, Shah
N
, Champlin
RE
, Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma
. Leuk Lymphoma
. 2015
;56
(3
):602
–7
.12.
Chng
WJ
, Huang
GF
, Chung
TH
, Ng
SB
, Gonzalez-Paz
N
, Troska-Price
T
, Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
. Leukemia
. 2011
;25
(6
):1026
–35
.13.
Misund
K
, Keane
N
, Stein
CK
, Asmann
YW
, Day
G
, Welsh
S
, MYC dysregulation in the progression of multiple myeloma
. Leukemia
. 2020
;34
(1
):322
–6
.14.
Rajkumar
SV
, Harousseau
JL
, Durie
B
, Anderson
KC
, Dimopoulos
M
, Kyle
R
, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
. Blood
. 2011
;117
(18
):4691
–5
.15.
Kanda
Y
. Investigation of the freely available easy-to-use software “EZR” for medical statistics
. Bone Marrow Transplant
. 2013
;48
(3
):452
–8
. .16.
Avet-Loiseau
H
, Attal
M
, Moreau
P
, Charbonnel
C
, Garban
F
, Hulin
C
, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
. Blood
. 2007
;109
(8
):3489
–95
.17.
Sharma
N
, Smadbeck
JB
, Abdallah
N
, Zepeda-Mendoza
C
, Binder
M
, Pearce
KE
, The prognostic role of MYC structual variants identified by NGS and FISH in multiple myeloma
. Clin Cancer Res
. 2021
;27
(19
):5430
–9
.18.
Dib
A
, Gabrea
A
, Glebov
OK
, Bergsagel
PL
, Kuehl
WM
. Characterization of MYC translocations in multiple myeloma cell lines
. J Natl Cancer Inst Monogr
. 2008
;39
:25
–31
. .19.
Iida
S
, Ueda
R
. Multistep tumorigenesis of multiple myeloma: its molecular delineation
. Int J Hematol
. 2003
;77
(3
):207
–12
. .20.
Kuehl
WM
, Bergsagel
PL
. Multiple myeloma: evolving genetic events and host interactions
. Nat Rev Cancer
. 2002
;2
(3
):175
–87
. .21.
Wu
KL
, Beverloo
B
, Velthuizen
SJ
, Sonneveld
P
. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression
. Clin Lymphoma Myeloma
. 2007
;7
(4
):280
–5
. .22.
Nishida
K
, Tamura
A
, Nakazawa
N
, Ueda
Y
, Abe
T
, Matsuda
F
, The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization
. Blood
. 1997
;90
(2
):526
–34
.23.
Chiecchio
L
, Dagrada
GP
, Protheroe
RK
, Stockley
DM
, Smith
AG
, Orchard
KH
, Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case
. Haematologica
. 2009
;94
(7
):1024
–8
.24.
Mikulasova
A
, Wardell
CP
, Murison
A
, Boyle
EM
, Jackson
GH
, Smetana
J
, The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
. Haematologica
. 2017
;102
(9
):1617
–25
.25.
Hanamura
I
, Stewart
JP
, Huang
Y
, Zhan
F
, Santra
M
, Sawyer
JR
, Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
. Blood
. 2006
;108
(5
):1724
–32
.26.
Di Bacco
A
, Bahlis
NJ
, Munshi
NC
, Avet-Loiseau
H
, Masszi
T
, Viterbo
L
, c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma
. Eur J Haematol
. 2020
;105
(1
):35
–46
.27.
Ludwig
H
, Poenisch
W
, Knop
S
, Egle
A
, Schreder
M
, Lechner
D
, Ixazomib-thalidomide-dexamethasone for induction therapy followed by ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
. Br J Cancer
. 2019
;121
(9
):751
–7
.28.
Dao
DD
, Sawyer
JR
, Epstein
J
, Hoover
RG
, Barlogie
B
, Tricot
G
. Deletion of the retinoblastoma gene in multiple myeloma
. Leukemia
. 1994
;8
(8
):1280
–4
.29.
Drach
J
, Schuster
J
, Nowotny
H
, Angerler
J
, Rosenthal
F
, Fiegl
M
, Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization
. Cancer Res
. 1995
;55
(17
):3854
–9
.30.
Zojer
N
, Königsberg
R
, Ackermann
J
, Fritz
E
, Dallinger
S
, Krömer
E
, Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
. Blood
. 2000
;95
(6
):1925
–30
.31.
Facon
T
, Avet-Loiseau
H
, Guillerm
G
, Moreau
P
, Geneviève
F
, Zandecki
M
, Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
. Blood
. 2001
;97
(6
):1566
–71
.32.
Shaughnessy
J
, Tian
E
, Sawyer
J
, Bumm
K
, Landes
R
, Badros
A
, High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
. Blood
. 2000
;96
(4
):1505
–11
.33.
Shaughnessy
J
, Tian
E
, Sawyer
J
, McCoy
J
, Tricot
G
, Jacobson
J
, Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
. Br J Haematol
. 2003
;120
(1
):44
–52
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
